Atossa Therapeutics (ATOS)

• Market cap: $121M
• 1 day: -1.66%
• 5 days: -13.18%
• 1 month: -19.69%
• 3 months: -33.99%
• 6 months: -13.18%
• Year to date: 3.07%
• 1 year: 32.38%
• 5 years: -37.42%
• 10 years: -99.46%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Employees: 10

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

494% more call options, than puts

Call options by funds: $1M | Put options by funds: $169K

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

31% more capital invested

Capital invested by funds: $31.7M [Q2] → $41.5M (+$9.77M) [Q3]

12% more funds holding

Funds holding: 77 [Q2] → 86 (+9) [Q3]

0.53% more ownership

Funds ownership: 21.22% [Q2] → 21.74% (+0.53%) [Q3]

24% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 25

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 626% upside
• Avg. target: $7 626% upside
• High target: $7 626% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target	626% upside $7	Buy Reiterated	13 Dec 2024
Ascendiant Capital Edward Woo 38% 1-year accuracy 28 / 73 met price target	626% upside $7	Buy Maintained	9 Dec 2024